Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Recurrence 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine phosphate 16Cyclophosphamide 16Antilymphocyte Serum 13Mycophenolic Acid 11Busulfan 11Radiotherapy 9Melphalan 9Cyclosporine 9Cord Blood Stem Cell Transplantation 9Peripheral Blood Stem Cell Transplantation 8Methylprednisolone 8Whole-Body Irradiation 6Tacrolimus 6Filgrastim 6Methotrexate 4fludarabine 3thymoglobulin 2Etoposide 2Cytarabine 2sargramostim 1niraparib 1merphos 1fanasil, pyrimethamine drug combination 1eltrombopag 1darinaparsin 1Transplantation 1Thiotepa 1Therapeutics 1Sirolimus 1Pharmacokinetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × darinaparsin × Classical hematology × Clear all
NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡